{Reference Type}: Journal Article
{Title}: Nisin Inhibition of Gram-Negative Bacteria.
{Author}: Charest AM;Reed E;Bozorgzadeh S;Hernandez L;Getsey NV;Smith L;Galperina A;Beauregard HE;Charest HA;Mitchell M;Riley MA;
{Journal}: Microorganisms
{Volume}: 12
{Issue}: 6
{Year}: 2024 Jun 19
{Factor}: 4.926
{DOI}: 10.3390/microorganisms12061230
{Abstract}: Aims: This study investigates the activity of the broad-spectrum bacteriocin nisin against a large panel of Gram-negative bacterial isolates, including relevant plant, animal, and human pathogens. The aim is to generate supportive evidence towards the use/inclusion of bacteriocin-based therapeutics and open avenues for their continued development. Methods and Results: Nisin inhibitory activity was screened against a panel of 575 strains of Gram-negative bacteria, encompassing 17 genera. Nisin inhibition was observed in 309 out of 575 strains, challenging the prevailing belief that nisin lacks effectiveness against Gram-negative bacteria. The genera Acinetobacter, Helicobacter, Erwinia, and Xanthomonas exhibited particularly high nisin sensitivity. Conclusions: The findings of this study highlight the promising potential of nisin as a therapeutic agent for several key Gram-negative plant, animal, and human pathogens. These results challenge the prevailing notion that nisin is less effective or ineffective against Gram-negative pathogens when compared to Gram-positive pathogens and support future pursuits of nisin as a complementary therapy to existing antibiotics. Significance and Impact of Study: This research supports further exploration of nisin as a promising therapeutic agent for numerous human, animal, and plant health applications, offering a complementary tool for infection control in the face of multidrug-resistant bacteria.